Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3334295 | Surgical Pathology Clinics | 2016 | 14 Pages |
Abstract
Application of next-generation sequencing (NGS) on myeloid neoplasms has expanded our knowledge of genomic alterations in this group of diseases. Genomic alterations in myeloid neoplasms are complex, heterogeneous, and not specific to a disease entity. NGS-based panel testing of myeloid neoplasms can complement existing diagnostic modalities and is gaining acceptance in the clinics and diagnostic laboratories. Prospective, randomized trials to evaluate the prognostic significance of genomic markers in myeloid neoplasms are under way in academic medical centers.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Frank C. Kuo,